| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA695431 | F | Compound was evaluated for its activity to inhibit growth of human breast cancer cell line | Homo sapiens | 1 | ALA1150526 | cell-based format | Scientific Literature | |
| 2. | ALA695432 | F | Cytotoxic activity against human breast cancer cell line | Homo sapiens | 7 | ALA1128647 | cell-based format | Scientific Literature | |
| 3. | ALA872039 | F | Percentage growth inhibition at a fixed concentration of 1.0*10e4 M against human breast cancer cell lines was determined after a 48 hr incubation | Homo sapiens | 3 | ALA1135000 | cell-based format | Scientific Literature | |
| 4. | ALA879733 | F | Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% | Homo sapiens | 7 | ALA1135805 | cell-based format | Scientific Literature | |
| 5. | ALA695433 | F | Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50% | Homo sapiens | 1 | ALA1135805 | cell-based format | Scientific Literature | |
| 6. | ALA695434 | F | Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%. | Homo sapiens | 6 | ALA1135805 | cell-based format | Scientific Literature | |
| 7. | ALA695435 | F | Tested for anticancer activity against human breast cancer | Homo sapiens | 5 | ALA1134421 | cell-based format | Scientific Literature | |
| 8. | ALA695436 | F | Tested for anticancer activity against human breast cancer; NT means Not tested | Homo sapiens | 1 | ALA1134421 | cell-based format | Scientific Literature | |
| 9. | ALA695437 | F | To estimate the extent of resistance conferred by Pgp, the ratio of IC50 in MDA-435/LCC6-MDR1 and MDA-435/LCC6 cells (relative resistance of Pgp-positive cells) was used; no data | Homo sapiens | 2 | ALA1135805 | cell-based format | Scientific Literature | |
| 10. | ALA695438 | F | Ratio of effect of compound on DOX accumulation (antiPgp activity) to its intrinsic cellular toxicity | Homo sapiens | 1 | ALA1135805 | cell-based format | Scientific Literature | |
| 11. | ALA695439 | F | Ratio of effect of compound on DOX accumulation (antiPgp activity) to its intrinsic cellular toxicity; | Homo sapiens | 6 | ALA1135805 | cell-based format | Scientific Literature | |
| 12. | ALA695440 | F | Ratio of effect of compound on VBL accumulation (antiPgp activity) to its intrinsic cellular toxicity | Homo sapiens | 2 | ALA1135805 | cell-based format | Scientific Literature | |
| 13. | ALA699276 | F | Ratio of effect of compound on VBL accumulation (antiPgp activity) to its intrinsic cellular toxicity; | Homo sapiens | 5 | ALA1135805 | cell-based format | Scientific Literature | |
| 14. | ALA694636 | F | Potency relative to progesterone in reducing the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells | Homo sapiens | 7 | ALA1135805 | cell-based format | Scientific Literature | |
| 15. | ALA694637 | F | Potency relative to progesterone in reducing the difference in reversing of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells | Homo sapiens | 7 | ALA1135805 | cell-based format | Scientific Literature | |
| 16. | ALA694638 | F | To estimate the extent of resistance conferred by Pgp, the ratio of IC50 in MDA-435/LCC6-MDR1 and MDA-435/LCC6 cells (relative resistance of Pgp-positive cells) was used | Homo sapiens | 5 | ALA1135805 | cell-based format | Scientific Literature | |
| 17. | ALA817971 | F | In vitro median growth inhibitory concentration against breast cancer cell lines | 8 | ALA1133460 | cell-based format | Scientific Literature | ||
| 18. | ALA817626 | F | In vitro growth inhibitory concentration against breast cancer cell lines | 11 | ALA1133460 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!